InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for First-line CLL/SLL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has obtained regulatory approval from...
Chipscreen Biosciences Cuts Private Placement Proceeds to RMB 950 Million
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has revised its private placement proceeds to RMB...
Shanghai Junshi Biosciences’ Loqtorzi Receives NMPA Approval for Melanoma Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received another...
Innovent Biologics’ Aoyixin Wins NMPA Approval for First-line NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another indication approval from...
CSPC Pharmaceutical Group Gains NMPA Approval for SYH2068 siRNA Clinical Trials
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has obtained approval from China’s National Medical Products...
Grand Pharma Group and Sirtex Medical US Launch Commercial Partnership in Medical Innovation
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its subsidiary Chengdu Shetai Medical...
Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South...
Digital-Intelligent Transformation of China’s Pharmaceutical Industry: 2025-2030 Plan Unveiled
China’s Ministry of Industry and Information Technology, Ministry of Commerce, National Health Commission (NHC), and...
Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development
China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (SHE: 300181) announced an investment of RMB 20 million...
Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...
LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline
Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round...
Amgen Announces $900M Investment to Expand Ohio Manufacturing
US biotech leader Amgen (NASDAQ: AMGN) announced a USD 900 million investment to expand its...
Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval...
Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received approval from the National...
Akeso’s Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC
China-based Akeso, Inc. (HKG: 9926) announced that its supplementary New Drug Application (sNDA) for ivonescimab,...
Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China
China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial...
Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received clearance from...
Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...
Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis
China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...
TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis
China-based TYK Medicines, Inc. (HKG: 2410) announced the formal submission of a pre-NDA communication package...